A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

May 12, 2025

Study Completion Date

May 12, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986360

Specified dose on specified days

DRUG

Docetaxel

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

DRUG

Capecitabine

Specified dose on specified days

Trial Locations (35)

1280

Local Institution - 0033, Ciudad Autónoma de Buenos Aires

1426

Local Institution - 0031, Buenos Aires

2010

Local Institution - 0010, Darlinghurst

2065

Local Institution - 0061, St Leonards

3199

Local Institution - 0063, Frankston

4120

Local Institution - 0008, Brisbane

10060

Local Institution - 0059, Candiolo

13273

Local Institution - 0049, Marseille

20089

Local Institution - 0057, Rozzano

28034

Local Institution - 0055, Madrid

28041

Local Institution - 0056, Madrid

28078

Local Institution - 0018, Huntersville

31059

Local Institution - 0050, Toulouse

35128

Local Institution - 0065, Padua

37203

Local Institution - 0028, Nashville

41013

Local Institution - 0064, Seville

45070

Local Institution - 0041, Zapopan

66460

Local Institution - 0039, Monterrey

70121

Local Institution - 0026, New Orleans

72424

Local Institution - 0037, Puebla City

75248

Local Institution - 0048, Paris

78229

Local Institution - 0027, San Antonio

84119

Local Institution - 0046, West Valley City

90025

Local Institution - 0029, Los Angeles

90067

Local Institution - 0051, Los Angeles

94800

Local Institution - 0052, Villejuif

7500921

Local Institution - 0047, Santiago

8330032

Local Institution - 0035, Santiago

8420383

Local Institution - 0034, Santiago

07601

Local Institution - 0001, Hackensack

C1430EGF

Local Institution - 0030, CABA

K1H 8L6

Local Institution - 0003, Ottawa

M5G 2M9

Local Institution - 0005, Toronto

03100

Local Institution - 0038, Mexico City

08036

Local Institution - 0053, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY